Pharmaceuticals

Iterum Therap

Iterum Therapeutics Obtains Patent for Treating Specific Diseases

Maxim Group Analyst Maintains Buy Rating on Iterum Therapeutics, Lows Price Target to $2

Iterum Therapeutics Third Quarter Earnings Call Shows Orlynda Market Performance

Iterum Therapeutics released FY2025 Q3 earnings on November 14 Pre-Market EST, actual revenue USD 390K (forecast USD 0), actual EPS USD -0.196 (forecast USD -0.09)

Iterum Therapeutics released FY2025 9 Months Earnings on November 14 Pre-Market EST, with actual revenue of USD 390K and EPS of USD -0.5026

Iterum Therapeutics to Release FY2025 Q3 Earnings on November 14, Pre-Market EST, Forecasted Revenue USD 0, EPS USD -0.09

McCarthy Focusing on Healthcare Sector and Specific Stocks

Iterum Therapeutics released FY2025 Semi-Annual earnings on August 5 Pre-Market (EST), actual revenue USD 0, actual EPS USD -0.3079

Iterum Therapeutics released FY2025 Q2 earnings on August 5 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1629 (forecast USD -0.11)

Iterum Therapeutics to Release FY2025 Q2 Earnings on August 5, Pre-Market EST, Forecast EPS USD -0.11

Iterum Therapeutics announces to combat multidrug-resistant pathogens

Iterum Therapeutics Appoints Christine Coyne As Chief Commercial Officer

Iterum Therapeutics and Eversana Sign ORLYNVAHTM Promotion Agreement

Iterum Therapeutics released FY2025 Q1 earnings on May 13 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1436 (forecast USD -0.14)

Iterum Therapeutics PLC Prepares for Q4 2025 Orlynvah(TM) Launch

Iterum Therapeutics to Report Quarterly Earnings

Iterum Therapeutics to release FY2025 Q1 earnings on May 13 Pre-Market EST, forecast revenue USD 2.683 M, EPS USD -0.15

Iterum Therapeutics released FY2024 Annual Earnings on February 7 During-Market (EST), Actual Revenue: 0 USD (Forecast: 0 USD), Actual EPS: -1.26 USD (Forecast: -1.15 USD)

Iterum Therapeutics released FY2024 Q4 earnings on February 7, 2025, during market hours (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -0.2483 USD (forecast -0.17 USD)

Iterum Therapeutics to Release FY2024 Q4 Earnings on February 7, 2025, During Market Hours EST, Forecasted EPS -0.17 USD

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SEOVF

ITRM

NBRVF

LABU

ARKG

Keenova Reports First Quarter 2026 Financial Results | MNK Stock News

StockTitan

Sernova Corp.

Nabriva Therapeutics plc

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VG Health

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Keenova Reports First Quarter 2026 Financial Results | MNK Stock News

Iterion Therapeutics announced that tegavivint will be featured in three presentations at the 2026 ASCO Annual Meeting, including an oral presentation of Phase 1/2 data in advanced hepatocellular carcinoma (HCC). The drug targets Wnt/β-catenin-driven cancers and aims to address the unmet need for patients with activating mutations in this pathway. The presentations will take place from May 29 to June 2, 2026, in Chicago, highlighting the growing interest in TBL1 as a therapeutic target.

prnewswire

08:09 ETIterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock News

iShares Global Healthcare

Health Care Select Sector SPDR

iShares US Pharma

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock News

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock News

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock News

ITRMF

Antibiotic resistance is escalating, yet investment in new antibiotics is declining. Iterum Therapeutics, after FDA approval for its antibiotic Orlynvah, faced financial struggles and announced plans to cease operations. The market punishes antibiotic developers due to high commercialization costs and low sales, despite the urgent need for new treatments. Policymakers are slow to act, with the U.S. lacking effective solutions like those in the UK and EU. The Pasteur Act aims to incentivize antibiotic development, but without systemic changes, more companies may face bankruptcy, jeopardizing patient care.

Thehill

ITERUM THERAPEUTICS PLC

Antibiotic resistance is growing — don't delay new antibiotics

Iterion Therapeutics announced the presentation of two abstracts on its first-in-class TBL1 inhibitor, tegavivint, at the 2026 AACR Annual Meeting. The drug targets the Wnt/β-catenin pathway, showing potent anti-tumor activity in preclinical models and clinical studies, particularly in hepatocellular carcinoma and colorectal cancer. The presentations will detail tegavivint's mechanism of action and its potential across various Wnt-driven cancers. The company is advancing its clinical strategy with a focus on hepatocellular carcinoma and expanding into other cancer types.

MorningStar

Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting

IINN

In Tuesday's after-market session, Iterum Therapeutics (ITRM) saw a significant gain of 37.0%, reaching $0.04, while Inspira Technologies Oxy (IINN) rose 11.01% to $0.5. Other gainers included Profusa (PFSA) up 9.13% to $0.55, and Omeros (OMER) up 7.96% to $11.4. Conversely, ORIC Pharmaceuticals (ORIC) fell 25.1% to $9.49, and BioAtla (BCAB) dropped 18.89% to $0.13. The Q4 earnings reports for several companies were released today, impacting stock movements.

benzinga_article

Inspira Tech OXY

Profusa

Omeros

Invesco Nasdaq Biotechnology ETF

12 Health Care Stocks Moving In Tuesday's After-Market Session

VRAX

PEPG

In Tuesday's intraday session, Apellis Pharmaceuticals saw a significant gain of 135.5%, reaching $40.26, with a market cap of $2.1 billion. Other notable gainers included Bullfrog AI Hldgs (+62.85%), Centessa Pharmaceuticals (+44.76%), and Virax Biolabs Group (+29.84%). Conversely, IO Biotech experienced a sharp decline of 73.2%, dropping to $0.05, followed by PepGen (-63.72%) and Iterum Therapeutics (-45.74%). The Q4 earnings reports influenced these movements, with several companies reporting significant changes in stock prices.

Virax Biolabs

Bullfrog AI

PepGen

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM)

Centessa Pharmaceuticals

IO Biotech

Apellis Pharma

IO BIOTECH INC

12 Health Care Stocks Moving In Tuesday's Intraday Session

In Tuesday's pre-market session, Apellis Pharmaceuticals saw a significant gain of 138.8%, reaching $40.81, with a market cap of $2.1 billion. Other notable gainers included Virax Biolabs (up 62.43%), Centessa Pharmaceuticals (up 47.49%), and Insight Molecular (up 34.9%). Conversely, PepGen experienced a sharp decline of 48.7%, followed by Iterum Therapeutics (down 32.53%) and Phreesia (down 24.19%). Several companies reported Q4 earnings recently, impacting stock movements.

Iterum Therap(ITRM.US)

Keenova Reports First Quarter 2026 Financial Results | MNK Stock News

08:09 ETIterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock News

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock News

Antibiotic resistance is growing — don't delay new antibiotics

Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session